Community-Acquired Skin & Skin Structure Infections are estimated to hold 62.0% by type of infection in 2026. Glycopeptides & Lipoglycopeptides are projected at 29.0% by drug class, while Parenteral administration is forecast at 56.0% of route demand. Hospital Pharmacies and Hospitals lead their categories as product selection remains tied to pathogen fit and stewardship rules.
Skin Structure Infections Market Analysis By Distribution ChannelSkin Structure Infections Market Analysis By Drug ClassSkin Structure Infections Market Analysis By End UserSkin Structure Infections Market Analysis By Route Of AdministrationSkin Structure Infections Market Opportunity Matrix Growth Vs ValueSkin Structure Infections Market Breakdown By Type Of Infection, Drug Class, And Region